A PHASE 1, OPEN-LABEL, CROSS-OVER, FIXED SEQUENCE STUDY TO EVALUATE THE EFFECT OF MULTIPLE DOSES OF DS-1971A ON THE SINGLE DOSE PHARMACOKINETICS OF PROBE SUBSTRATES FOR CYP2B6, CYP2C8, CYP2C9, CYP2C19 AND CYP3A4 ENZYMES IN HEALTHY MALE AND FEMALE SUBJECTS

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

May 31, 2015

Primary Completion Date

July 31, 2015

Study Completion Date

July 31, 2015

Conditions

Healthy

Interventions

DRUG

DS-1971a

200mg tablet

DRUG

midazolam hydrochloride

2.5mg oromucosal liquid

DRUG

Omeprazole

20mg gastro-resistant capsule

DRUG

Pioglitazone hydrochloride

15mg tablet

DRUG

Buproprion

150mg Prolonged release tablet

DRUG

Tolbutamide

500mg tablet

Trial Locations (1)

London